Treatment of generalized hyperhidrosis with oxybutynin in post-menopausal patients

Acta Derm Venereol. 2010 May;90(3):291-3. doi: 10.2340/00015555-0828.


Postmenopausal hyperhidrosis is a form of secondary hyperhidrosis, and hormone-replacement therapy is a commonly used therapeutic option. However, some women do not benefit from this treatment, and oral anticholinergics are a logical alternative for reducing generalized sweating in these patients. Twenty-one patients were medicated with 5 or 10 mg of oxybutynin per day. After a 3-month follow-up period, efficacy was assessed with the Hyperhidrosis Disease Severity Scale (HDSS) and the Dermatology Life Quality Index (DLQI) was used to assess the improvement in patients' quality of life. The HDSS score was 3.2 +/- 0.4 (mean +/- SD) before medication and 1.9 +/- 0.4 after 3 months. The baseline DLQI score of 8.4 +/- 1.0 was reduced to 4.4 +/- 0.9. No serious side-effects or adverse events resulted from treatment. Oxybutynin was a well-tolerated, effective, and safe method for treating postmenopausal sweating. However, long-term medication and the limited effects of the treatment were disadvantages.

MeSH terms

  • Female
  • Humans
  • Hyperhidrosis / drug therapy*
  • Hyperhidrosis / physiopathology
  • Mandelic Acids / adverse effects
  • Mandelic Acids / therapeutic use*
  • Middle Aged
  • Muscarinic Antagonists / adverse effects
  • Muscarinic Antagonists / therapeutic use*
  • Postmenopause
  • Prospective Studies
  • Quality of Life
  • Severity of Illness Index
  • Surveys and Questionnaires
  • Sweating / drug effects*
  • Time Factors
  • Treatment Outcome


  • Mandelic Acids
  • Muscarinic Antagonists
  • oxybutynin